A Randomized Open-Label Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination with Immune Checkpoint Blockade for Patients with Colon Cancer with Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chem | NYU Langone Health

Go Back to All Clinical Trials

A Randomized Open-Label Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination with Immune Checkpoint Blockade for Patients with Colon Cancer with Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chem

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Colon Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:
1. Have a confirmed diagnosis of high-risk stage II or stage III MSS-colon cancer.
2. Have adequate organ function.
3. ECOG performance status of 0 to 1.

You may not be eligible for this study if the following are true:

1. Patients with Microsatellite instable (MSI) high disease based on institutional standard.
2. Patients with known tumor mutational burden (TMB) <1 non-synonymous mutations/megabase.
3. Bleeding disorder (e.g., factor deficiency, coagulopathy) or history of significant bruising or bleeding following intramuscular (IM) injections or blood draws.
4. Patients receiving treatment with investigational products and/or other anti-cancer therapies.